Croisile B, Trillet M, Fondarai J, Laurent B, Mauguière F, Billardon M
Department of Neurology, Hôpital Neurologique, Lyon, France.
Neurology. 1993 Feb;43(2):301-5. doi: 10.1212/wnl.43.2.301.
Preclinical research suggests that piracetam (a nootropic drug) may improve cognitive functions, but previous studies have failed to demonstrate a clear benefit for the treatment of Alzheimer's disease (AD). We report a 1-year, double-blind, placebo-controlled, parallel-group study with a high dose of piracetam (8 g/d per os) in 33 ambulant patients with early probable AD. Thirty subjects completed the 1-year study. No improvement occurred in either group, but our results support the hypothesis that long-term administration of high doses of piracetam might slow the progression of cognitive deterioration in patients with AD. The most significant differences concerned the recall of pictures series and recent incident and remote memory. The drug was well-tolerated.
临床前研究表明，吡拉西坦（一种益智药）可能改善认知功能，但此前的研究未能证明其对治疗阿尔茨海默病（AD）有明显益处。我们报告了一项为期1年的双盲、安慰剂对照、平行组研究，对33例早期可能患有AD的门诊患者使用高剂量吡拉西坦（口服8克/天）。30名受试者完成了1年的研究。两组均未出现改善，但我们的结果支持这样的假设，即长期给予高剂量吡拉西坦可能会减缓AD患者认知衰退的进展。最显著的差异在于图片系列回忆以及近期事件和远期记忆方面。该药物耐受性良好。
